한글목차

세계의 COX-2 억제제 시장 전망은 병원 약국, 소매 약국, 온라인 약국 시장에 기회가 있고 유망시되고 있습니다. 세계 COX-2 억제제 시장은 2025-2031년 연평균 복합 성장률(CAGR) 12.5%를 보일 것으로 예측됩니다. 이 시장의 주요 촉진요인은 더 안전한 진통제에 대한 수요 증가, 세계적인 골관절염의 유병률 증가, 선택적 약효에 대한 의식 증가입니다.

• Lucintel의 예측에 의하면, 유형별로는 선택약이 예측 기간 중에 높은 성장을 이룰 전망입니다.
• 용도별로는 온라인 약국이 가장 높은 성장이 예상됩니다.
• 지역별로는 아시아태평양이 예측 기간 동안 가장 높은 성장이 예상됩니다.

COX-2 억제제 시장의 새로운 동향

COX-2 억제제 시장은 제약 연구의 진보, 통증 경로의 이해의 심화, 치료 효과와 안전성의 균형을 유지할 필요성의 지속에 의해 형성되어 지속적인 진화를 이루고 있습니다. 새로운 동향은 환자의 결과를 개선하고 이러한 중요한 약물의 유용성을 확대하는 기술 혁신을 추진하고 있습니다.

• 맞춤형 의료 접근법 : COX-2 억제제의 처방에서 맞춤형 의료를 목표로하는 새로운 동향이 있습니다. 이는 유전자 마커 및 환자 프로파일을 이용하여 개별 반응 및 잠재적인 부작용을 예측하고, 효능을 극대화하고, 위험(특히 심혈관계 위험)을 최소화하기 위해 더욱 맞춤화된 치료 요법을 가능하게 합니다.
• 보다 안전하고 선택성이 높은 억제제 개발 : 연구개발의 초점은 안전성 프로파일을 개선한 차세대 COX-2 억제제의 설계로 좁혀지고 있습니다. 이 경향은 COX-2에 대한 높은 선택성을 유지하면서 심혈관계와 신장의 부작용을 완화시키는 분자를 창출하는 것을 목표로 하며, 이 클래스와 관련된 역사적인 과제를 다루는 것입니다.
• 다른 통증 치료제와의 병용 요법 : 새로운 동향은 COX-2 억제제와 다른 통증 관리 전략의 조합을 포함합니다. 여기에는 진통제, 신경장애성 통증 치료제, 비약리학적 개입제와의 병용이 포함되며, 시너지 효과에 의해 각 약제의 투여량을 적게 하여 보다 좋은 통증 조절을 달성하는 것을 목표로 합니다.
• 새로운 치료로 확대 : COX-2 억제제는 기존의 염증성 질환뿐만 아니라 새로운 치료에 응용할 것으로 기대됩니다. 이 동향에는 암 예방과 치료, 특정 신경질환, 기타 염증이 중요한 역할을 하는 질환 등 분야에서의 가능성 조사도 포함되어 시장의 다양화가 진행되고 있습니다.
• 고급 약물전달 시스템 : COX-2 억제제의 새로운 약물전달 시스템의 개발은 새로운 추세입니다. 여기에는 생체이용률 향상, 투여 횟수 감소, 전신 부작용 최소화를 목적으로 하는 서방형 제형, 경피 패치 또는 표적 전달 메커니즘이 포함되어 환자의 컴플라이언스와 안전성을 향상시킬 수 있습니다.

이러한 새로운 추세는 COX-2 억제제 시장을 근본적으로 재구성하고 있으며, 보다 정확하고 안전하며 다재다능한 치료법을 선택하고 있습니다. 이러한 추세는 약물 설계, 처방 방법 및 치료 응용 분야에서 혁신을 촉진하고 궁극적으로 리스크 혜택 프로파일을 최적화하고 보다 광범위한 환자 및 병리학에 대한 COX-2 억제제의 유용성을 확대하는 것을 목표로 하고 있습니다.

COX-2 억제제 시장의 최근 동향

COX-2 억제제 시장은 안전성 프로파일의 향상, 치료적 유용성의 확대, 규제 상황의 변화에 대한 대응 등 지속적인 노력에 견인되어 최근 몇 가지 중요한 동향을 경험하고 있습니다. 이러한 진보는 통증과 염증 관리에서 COX-2 억제제의 역할을 확고하게 하기 위한 것입니다.

• 심혈관 안전성 시험의 중요성 최근의 주요 동향은 기존 COX-2 억제제, 특히 셀레콕시브의 심혈관 위험 프로파일을 더 잘 이해하기 위해 엄격한 시판 후 조사 및 임상시험이 계속 중시되고 있다는 것입니다. 이를 통해 처방자는 충분한 정보에 근거한 의사 결정과 환자의 위험 계층화를 위한 종합적인 데이터를 얻을 수 있습니다.
• 기존 약물 재사용 검토 : 기존 COX-2 억제제를 기존 통증과 염증 이외의 새로운 적응증으로 재사용하기 위한 조사 동향이 활발해지고 있습니다. 여기에는 종양학(대장암 예방 등)과 신경퇴행성 질환의 가능성을 탐구하는 것도 포함되어 항염증 작용을 활용하여 새로운 치료의 길을 엽니다.
• 외용제 및 주사제의 개발 : 최근의 동향으로는 COX-2 억제제의 외용 겔이나 주사액(예 : 수술 후 통증에 대한 부피바카인/멜록시컴 배합제) 등의 대체 제제의 개발 및 승인을 들 수 있습니다. 이들은 국소 진통을 목적으로 하며 전신 부작용을 줄이고 환자의 편의성을 향상시킬 수 있습니다.
• 제네릭 의약품의 보급 : COX-2 억제제, 특히 셀레콕시브의 제네릭 의약품의 가용성과 보급이 계속되고 있습니다. 이를 통해 환자에게 사용하기 쉽고 구입하기 쉬운 가격이 되어 전반적인 비용을 낮추고 다양한 의료 시스템에서 이러한 약물을 널리 사용할 수 있습니다.
• 규제 당국의 검토 및 가이드라인 강화 : COX-2 억제제를 안전하고 적절하게 사용하기 위한 최신 지침 및 권장사항이 세계 규제 당국으로부터 계속 발표되고 있습니다. 이는 잠재적인 부작용을 최소화하고 합리적인 처방을 촉진하기 위해 환자 선택, 용량 최적화 및 모니터링의 중요성을 강조하는 균형 잡힌 접근법을 보장합니다.

이러한 최근의 동향은 COX-2 억제제의 사용에 신중하면서도 혁신적인 접근을 촉진함으로써 COX-2 억제제 시장에 큰 영향을 미치고 있습니다. COX-2 억제제의 위험 혜택 프로파일을 보다 깊게 이해하고, 치료 가능성을 확대하고, 약물 전달 방법을 개선하고, 이 중요한 통증 관리 약물에 대한 접근이 보다 넓고, 보다 안전하게 확보되고 있습니다.

목차

제1장 주요 요약

제2장 시장 개요

• 배경과 분류
• 공급망

제3장 시장 동향과 예측 분석

• 업계의 촉진요인과 과제
• PESTLE 분석
• 특허 분석
• 규제 환경

제4장 세계의 COX-2 억제제 시장 : 유형별

• 개요
• 매력 분석 : 유형별
• 선택약 : 동향과 예측(2019-2031년)
• 비선택약 : 동향과 예측(2019-2031년)

제5장 세계의 COX-2 억제제 시장 : 용도별

• 개요
• 매력 분석 : 용도별
• 병원 약국 : 동향과 예측(2019-2031년)
• 소매 약국 : 동향과 예측(2019-2031년)
• 온라인 약국 : 동향과 예측(2019-2031년)

제6장 지역 분석

• 개요
• 세계의 COX-2 억제제 시장 : 지역별

제7장 북미의 COX-2 억제제 시장

• 개요
• 북미의 COX-2 억제제 시장 : 유형별
• 북미의 COX-2 억제제 시장 : 용도별
• 미국의 COX-2 억제제 시장
• 멕시코의 COX-2 억제제 시장
• 캐나다의 COX-2 억제제 시장

제8장 유럽의 COX-2 억제제 시장

• 개요
• 유럽의 COX-2 억제제 시장 : 유형별
• 유럽의 COX-2 억제제 시장 : 용도별
• 독일의 COX-2 억제제 시장
• 프랑스의 COX-2 억제제 시장
• 스페인의 COX-2 억제제 시장
• 이탈리아의 COX-2 억제제 시장
• 영국의 COX-2 억제제 시장

제9장 아시아태평양의 COX-2 억제제 시장

• 개요
• 아시아태평양의 COX-2 억제제 시장 : 유형별
• 아시아태평양의 COX-2 억제제 시장 : 용도별
• 일본의 COX-2 억제제 시장
• 인도의 COX-2 억제제 시장
• 중국의 COX-2 억제제 시장
• 한국의 COX-2 억제제 시장
• 인도네시아의 COX-2 억제제 시장

제10장 기타 지역(ROW)의 COX-2 억제제 시장

• 개요
• ROW의 COX-2 억제제 시장 : 유형별
• ROW의 COX-2 억제제 시장 : 용도별
• 중동의 COX-2 억제제 시장
• 남미의 COX-2 억제제 시장
• 아프리카의 COX-2 억제제 시장

제11장 경쟁 분석

• 제품 포트폴리오 분석
• 운영 통합
• Porter's Five Forces 분석
  • 경쟁 기업간 경쟁 관계
  • 바이어의 협상력
  • 공급자의 협상력
  • 대체품의 위협
  • 신규 참가업체의 위협
• 시장 점유율 분석

제12장 기회와 전략 분석

• 밸류체인 분석
• 성장 기회 분석
  • 성장 기회 : 유형별
  • 성장 기회 : 용도별
• 세계 COX-2 억제제 시장의 새로운 동향
• 전략 분석
  • 신제품 개발
  • 인증 및 라이선싱
  • 기업 인수합병(M&A), 계약, 제휴, 합작 사업

제13장 밸류체인의 주요 기업 프로파일

• 경쟁 분석
• Bayer
• Novartis
• Pfizer
• Merck
• Cadila Pharmaceuticals

제14장 부록

• 그림 일람
• 표 일람
• 분석 방법
• 면책사항
• 저작권
• 약어와 기술 단위
• Lucintel 소개
• 문의

영문목차

The future of the global cox-2 inhibitor market looks promising with opportunities in the hospital pharmacy, retail pharmacy, and online pharmacy markets. The global cox-2 inhibitor market is expected to grow with a CAGR of 12.5% from 2025 to 2031. The major drivers for this market are the increasing demand for safer pain medications, the rising prevalence of osteoarthritis globally, and the growing awareness of selective drug benefits.

• Lucintel forecasts that, within the type category, selective is expected to witness higher growth over the forecast period.
• Within the application category, online pharmacy is expected to witness the highest growth.
• In terms of region, APAC is expected to witness the highest growth over the forecast period.

Emerging Trends in the Cox-2 Inhibitor Market

The COX-2 inhibitor market is undergoing continuous evolution, shaped by advancements in pharmaceutical research, growing understanding of pain pathways, and the ongoing need to balance therapeutic efficacy with safety. Emerging trends are driving innovation to improve patient outcomes and expand the utility of these important drugs.

• Personalized Medicine Approaches: There's an emerging trend towards personalized medicine in COX-2 inhibitor prescribing. This involves utilizing genetic markers and patient profiles to predict individual responses and potential side effects, allowing for more tailored treatment regimens to maximize efficacy and minimize risks, particularly cardiovascular ones.
• Development of Safer and More Selective Inhibitors: Research and development efforts are increasingly focused on designing next-generation COX-2 inhibitors with improved safety profiles. This trend aims to create molecules that maintain high selectivity for COX-2 while mitigating cardiovascular or renal side effects, addressing the historical challenges associated with the class.
• Combination Therapies with Other Pain Modalities: An emerging trend is the use of COX-2 inhibitors in combination with other pain management strategies. This includes co-prescription with analgesics, neuropathic pain medications, or non-pharmacological interventions, aiming for synergistic effects to achieve better pain control with potentially lower doses of each drug.
• Expansion into Novel Therapeutic Applications: Beyond traditional inflammatory conditions, there's growing interest in exploring new therapeutic applications for COX-2 inhibitors. This trend includes investigating their potential in areas like cancer prevention and treatment, certain neurological disorders, and other conditions where inflammation plays a significant role, diversifying their market.
• Advanced Drug Delivery Systems: The development of novel drug delivery systems for COX-2 inhibitors is an emerging trend. This includes slow-release formulations, transdermal patches, or targeted delivery mechanisms aimed at improving bioavailability, reducing dosing frequency, and potentially minimizing systemic side effects, thereby enhancing patient compliance and safety.

These emerging trends are fundamentally reshaping the COX-2 inhibitor market by pushing for more precise, safer, and versatile therapeutic options. They are driving innovation in drug design, prescribing practices, and therapeutic applications, ultimately aiming to optimize the risk-benefit profile and expand the utility of COX-2 inhibitors for a broader range of patients and conditions.

Recent Developments in the Cox-2 Inhibitor Market

The COX-2 inhibitor market has experienced several key recent developments, primarily driven by ongoing efforts to enhance their safety profile, expand their therapeutic utility, and adapt to evolving regulatory landscapes. These advancements aim to solidify their role in pain and inflammation management.

• Focus on Cardiovascular Safety Studies: A major recent development is the continued emphasis on rigorous post-marketing surveillance and clinical studies to better understand the cardiovascular risk profile of existing COX-2 inhibitors, particularly Celecoxib. This ensures prescribers have comprehensive data for informed decision-making and patient risk stratification.
• Exploration of Repurposing Existing Drugs: There's an increasing trend in researching the repurposing of existing COX-2 inhibitors for novel indications beyond traditional pain and inflammation. This includes exploring their potential in oncology (e.g., colorectal cancer prevention) and neurodegenerative diseases, leveraging their anti-inflammatory properties for new therapeutic avenues.
• Development of Topical and Injectable Formulations: Recent advancements include the development and approval of alternative formulations, such as topical gels or injectable solutions for COX-2 inhibitors (e.g., bupivacaine/meloxicam combination for postoperative pain). These aim to provide localized pain relief, potentially reducing systemic side effects and improving patient convenience.
• Increased Generic Penetration: The market has seen a continued rise in the availability and adoption of generic versions of COX-2 inhibitors, particularly celecoxib. This increases accessibility and affordability for patients, driving down overall costs and making these drugs more widely available in various healthcare systems.
• Enhanced Regulatory Scrutiny and Guidelines: Regulatory bodies globally continue to issue updated guidelines and recommendations for the safe and appropriate use of COX-2 inhibitors. This ensures a balanced approach, emphasizing the importance of patient selection, dose optimization, and monitoring, to minimize potential adverse effects and promote rational prescribing.

These recent developments are significantly impacting the COX-2 inhibitor market by fostering a more cautious yet innovative approach to their use. They are leading to a deeper understanding of their risk-benefit profile, expanding their therapeutic potential, improving delivery methods, and ensuring broader, yet safer, access to these essential pain management drugs.

Strategic Growth Opportunities in the Cox-2 Inhibitor Market

The COX-2 inhibitor market presents strategic growth opportunities across key applications, driven by the persistent global burden of pain and inflammatory conditions. Capitalizing on these opportunities requires a nuanced understanding of patient needs and the specific therapeutic benefits offered by COX-2 selective inhibition.

• Osteoarthritis Management: With the aging global population, osteoarthritis remains a primary application. Strategic growth involves promoting COX-2 inhibitors for long-term pain and inflammation control in OA patients, emphasizing their gastrointestinal safety profile compared to traditional NSAIDs, and supporting patient adherence for chronic management.
• Rheumatoid Arthritis Treatment: RA is a chronic autoimmune inflammatory disease requiring consistent pain relief and inflammation reduction. Opportunities lie in positioning COX-2 inhibitors as a valuable component of multimodal RA treatment regimens, particularly for symptom management, while considering their use alongside disease-modifying antirheumatic drugs (DMARDs).
• Acute Postoperative Pain: The demand for effective and safe pain control post-surgery offers significant growth. Strategic opportunities include utilizing injectable or fast-acting COX-2 inhibitors for managing acute postoperative pain, potentially reducing opioid reliance and improving patient recovery with their anti-inflammatory and analgesic properties.
• Dysmenorrhea Management: COX-2 inhibitors are effective for menstrual pain. Growth opportunities involve highlighting their efficacy in managing dysmenorrhea, especially for patients who experience significant pain or gastrointestinal discomfort with non-selective NSAIDs, promoting them as a preferred option for this common condition.
• Targeting Chronic Low Back Pain: Chronic low back pain affects a large population globally. Strategic growth can be achieved by emphasizing the role of COX-2 inhibitors in the long-term management of chronic low back pain, particularly where an inflammatory component is identified, and integrating them into comprehensive pain management plans.

These strategic growth opportunities are profoundly impacting the COX-2 inhibitor market by reinforcing their vital role in managing specific pain and inflammatory conditions where their selective action provides distinct advantages. They are driving targeted marketing, clinical education, and potential new formulations to address unmet needs in these prevalent applications.

Cox-2 Inhibitor Market Driver and Challenges

The COX-2 inhibitor market is influenced by various technological, economic, and regulatory factors. Understanding these drivers and challenges is crucial for stakeholders to navigate the evolving landscape, foster innovation, and effectively meet the growing demand for safe and effective pain and inflammation management.

The factors responsible for driving the cox-2 inhibitor market include:

1. Increasing Prevalence of Inflammatory Diseases: The global rise in chronic inflammatory conditions such as osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis is a primary market driver. These conditions necessitate effective pain and inflammation management, directly fueling the demand for COX-2 inhibitors.

2. Favorable Gastrointestinal Safety Profile: Compared to traditional non-selective NSAIDs, COX-2 inhibitors offer a reduced risk of gastrointestinal side effects like ulcers and bleeding. This superior GI safety profile is a major driver, making them a preferred choice for patients at high risk of these complications.

3. Growing Geriatric Population: The world's aging population is more susceptible to age-related inflammatory conditions and chronic pain. This demographic shift directly increases the patient pool requiring long-term pain management solutions, thus driving the demand for COX-2 inhibitors.

4. Demand for Effective Pain Management: There is a continuous and increasing global demand for effective pain management solutions across acute and chronic conditions. COX-2 inhibitors provide potent analgesic and anti-inflammatory effects, making them a valuable tool in addressing this widespread need.

5. Advancements in Drug Formulation: Ongoing research and development in drug delivery systems and formulations for COX-2 inhibitors, such as extended-release tablets or combination products, improve patient compliance and reduce side effects. These innovations enhance the overall therapeutic profile, driving market growth.

Challenges in the cox-2 inhibitor market are:

1. Cardiovascular Safety Concerns: The most significant challenge remains the historical association of certain COX-2 inhibitors with increased cardiovascular risks, including heart attacks and strokes. This concern has led to market withdrawals and stringent regulatory oversight, limiting widespread adoption and impacting physician prescribing patterns.

2. Stringent Regulatory Oversight: Due to past safety issues, COX-2 inhibitors are subject to rigorous regulatory scrutiny globally. Obtaining and maintaining market approval requires extensive clinical trials and post-marketing surveillance, increasing development costs and approval timelines, posing a significant barrier to new entrants.

3. Competition from Alternatives: The market faces intense competition from a wide array of alternative pain management therapies, including traditional NSAIDs, opioids, biologics for inflammatory conditions, and non-pharmacological interventions. This competitive landscape puts pressure on pricing and market share for COX-2 inhibitors.

The COX-2 inhibitor market is predominantly driven by the escalating prevalence of inflammatory diseases, their superior gastrointestinal safety compared to traditional NSAIDs, and the increasing demand from an aging population for effective pain management. However, significant challenges, particularly concerns over cardiovascular safety and stringent regulatory oversight, alongside intense competition from alternative therapies, necessitate continuous innovation and careful risk-benefit assessment for sustained growth and ensuring their appropriate place in modern pain management protocols.

List of Cox-2 Inhibitor Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies cox-2 inhibitor companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the cox-2 inhibitor companies profiled in this report include-

• Bayer
• Novartis
• Pfizer
• Merck
• Cadila Pharmaceuticals

Cox-2 Inhibitor Market by Segment

The study includes a forecast for the global cox-2 inhibitor market by type, application, and region.

Cox-2 Inhibitor Market by Type [Value from 2019 to 2031]:

• Selective
• Non Selective

Cox-2 Inhibitor Market by Application [Value from 2019 to 2031]:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Cox-2 Inhibitor Market by Region [Value from 2019 to 2031]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Cox-2 Inhibitor Market

The COX-2 inhibitor market is navigating a complex environment characterized by increasing demand for pain management, particularly for chronic inflammatory conditions, balanced against persistent safety concerns and stringent regulatory oversight. Recent developments focus on enhancing the risk-benefit profile of existing drugs, exploring new applications, and developing novel formulations to address patient needs effectively.

• United States: The U.S. market continues to be dominated by Celecoxib (Celebrex), which remains the only selective COX-2 inhibitor widely available. Recent developments focus on managing the long-term safety profile, with ongoing post-marketing surveillance and research into personalized medicine approaches to minimize cardiovascular risks for patients.
• China: China's market for COX-2 inhibitors is expanding due to a rising prevalence of inflammatory conditions and growing healthcare expenditure. Developments include increased domestic production of generic versions, efforts to improve drug accessibility, and a focus on balancing efficacy with safety guidelines for widespread use across its large population.
• Germany: Germany's market emphasizes a cautious approach to COX-2 inhibitors, prioritizing patient safety and evidence-based medicine. Recent developments involve rigorous post-marketing surveillance, a focus on appropriate prescribing practices to mitigate cardiovascular risks, and continued research into the precise patient populations benefiting most from these drugs.
• India: India's COX-2 inhibitor market is experiencing significant growth, driven by the increasing incidence of musculoskeletal disorders and rising awareness of pain management. Developments include the availability of multiple generic formulations, a focus on affordability, and efforts to educate healthcare professionals on the appropriate use and potential risks of these medications.
• Japan: Japan's market for COX-2 inhibitors is characterized by a strong emphasis on precision and patient safety. Recent developments include careful monitoring of cardiovascular side effects, research into unique patient responses, and a steady demand for selective COX-2 inhibitors for chronic pain conditions within its aging population.

Features of the Global Cox-2 Inhibitor Market

• Market Size Estimates: Cox-2 inhibitor market size estimation in terms of value ($B).
• Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.
• Segmentation Analysis: Cox-2 inhibitor market size by type, application, and region in terms of value ($B).
• Regional Analysis: Cox-2 inhibitor market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
• Growth Opportunities: Analysis of growth opportunities in different types, applications, and regions for the cox-2 inhibitor market.
• Strategic Analysis: This includes M&A, new product development, and competitive landscape of the cox-2 inhibitor market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the cox-2 inhibitor market by type (selective and non selective), application (hospital pharmacies, retail pharmacies, and online pharmacies), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Market Overview

• 2.1 Background and Classifications
• 2.2 Supply Chain

3. Market Trends & Forecast Analysis

• 3.2 Industry Drivers and Challenges
• 3.3 PESTLE Analysis
• 3.4 Patent Analysis
• 3.5 Regulatory Environment

4. Global Cox-2 Inhibitor Market by Type

• 4.1 Overview
• 4.2 Attractiveness Analysis by Type
• 4.3 Selective: Trends and Forecast (2019-2031)
• 4.4 Non Selective: Trends and Forecast (2019-2031)

5. Global Cox-2 Inhibitor Market by Application

• 5.1 Overview
• 5.2 Attractiveness Analysis by Application
• 5.3 Hospital Pharmacies: Trends and Forecast (2019-2031)
• 5.4 Retail Pharmacies: Trends and Forecast (2019-2031)
• 5.5 Online Pharmacies: Trends and Forecast (2019-2031)

6. Regional Analysis

• 6.1 Overview
• 6.2 Global Cox-2 Inhibitor Market by Region

7. North American Cox-2 Inhibitor Market

• 7.1 Overview
• 7.2 North American Cox-2 Inhibitor Market by Type
• 7.3 North American Cox-2 Inhibitor Market by Application
• 7.4 United States Cox-2 Inhibitor Market
• 7.5 Mexican Cox-2 Inhibitor Market
• 7.6 Canadian Cox-2 Inhibitor Market

8. European Cox-2 Inhibitor Market

• 8.1 Overview
• 8.2 European Cox-2 Inhibitor Market by Type
• 8.3 European Cox-2 Inhibitor Market by Application
• 8.4 German Cox-2 Inhibitor Market
• 8.5 French Cox-2 Inhibitor Market
• 8.6 Spanish Cox-2 Inhibitor Market
• 8.7 Italian Cox-2 Inhibitor Market
• 8.8 United Kingdom Cox-2 Inhibitor Market

9. APAC Cox-2 Inhibitor Market

• 9.1 Overview
• 9.2 APAC Cox-2 Inhibitor Market by Type
• 9.3 APAC Cox-2 Inhibitor Market by Application
• 9.4 Japanese Cox-2 Inhibitor Market
• 9.5 Indian Cox-2 Inhibitor Market
• 9.6 Chinese Cox-2 Inhibitor Market
• 9.7 South Korean Cox-2 Inhibitor Market
• 9.8 Indonesian Cox-2 Inhibitor Market

10. ROW Cox-2 Inhibitor Market

• 10.1 Overview
• 10.2 ROW Cox-2 Inhibitor Market by Type
• 10.3 ROW Cox-2 Inhibitor Market by Application
• 10.4 Middle Eastern Cox-2 Inhibitor Market
• 10.5 South American Cox-2 Inhibitor Market
• 10.6 African Cox-2 Inhibitor Market

11. Competitor Analysis

• 11.1 Product Portfolio Analysis
• 11.2 Operational Integration
• 11.3 Porter's Five Forces Analysis
  • Competitive Rivalry
  • Bargaining Power of Buyers
  • Bargaining Power of Suppliers
  • Threat of Substitutes
  • Threat of New Entrants
• 11.4 Market Share Analysis

12. Opportunities & Strategic Analysis

• 12.1 Value Chain Analysis
• 12.2 Growth Opportunity Analysis
  • 12.2.1 Growth Opportunities by Type
  • 12.2.2 Growth Opportunities by Application
• 12.3 Emerging Trends in the Global Cox-2 Inhibitor Market
• 12.4 Strategic Analysis
  • 12.4.1 New Product Development
  • 12.4.2 Certification and Licensing
  • 12.4.3 Mergers, Acquisitions, Agreements, Collaborations, and Joint Ventures

13. Company Profiles of the Leading Players Across the Value Chain

• 13.1 Competitive Analysis
• 13.2 Bayer
  • Company Overview
  • Cox-2 Inhibitor Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.3 Novartis
  • Company Overview
  • Cox-2 Inhibitor Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.4 Pfizer
  • Company Overview
  • Cox-2 Inhibitor Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.5 Merck
  • Company Overview
  • Cox-2 Inhibitor Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.6 Cadila Pharmaceuticals
  • Company Overview
  • Cox-2 Inhibitor Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing

14. Appendix

• 14.1 List of Figures
• 14.2 List of Tables
• 14.3 Research Methodology
• 14.4 Disclaimer
• 14.5 Copyright
• 14.6 Abbreviations and Technical Units
• 14.7 About Us
• 14.8 Contact Us